Gewinn- und Verlustrechnung von Morgan Stanley

Financial sector stocks are ripping into their second quarter earnings reports. Wall Street analysts think the strength is justified.

Morgan Stanley (NYSE:MS) will release its second quarter earnings report before the opening bell on Wednesday, July 15.

The financial-technology stock was the biggest riser in the S&P 500 ahead of the open, despite broader tech weakness.

Vertex snaps up Crinetics, Synopsys pivots to higher-margin AI offerings, and more

NEW YORK--(BUSINESS WIRE)--Morgan Stanley Investment Management (MSIM), through investment funds managed by Morgan Stanley Infrastructure Partners (MSIP), its private infrastructure investment platform, today announced an investment in Greenlight Electricity Centre, a 932-megawatt gas-fired combined cycle power generation project in Sturgeon County, Alberta. MSIP is investing alongside large-cap company, Pembina Pipeline Corporation (Pembina), and Kineticor Asset Management (Kineticor) to suppo.

Morgan Stanley (MS) remains a Buy, supported by robust profitability, strong capital position, and continued asset inflows despite a tighter risk/reward after a 22% stock rally. Wealth Management and Institutional Securities both delivered strong Q1 growth, with pre-tax margins over 30% and ROTCE of 27.1%, exceeding management's 20% target. Capital returns are rising, with a $20B buyback and higher dividends, backed by a 15.1% CET1 ratio and disciplined risk management.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Talga Group Ltd (ASX:TLG, OTCQX:TLGRF, FRA:TGX) has begun commercial deliveries of its flagship battery graphite anode product Talnode®-C to Nyobolt under a...

St George Mining Ltd (ASX:SGQ, FRA:S0G, OTC:SGQMF) earlier this week said it had delivered its thickest mineralised intercept to date at the 100%-owned...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) earlier this week reported the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or...